Drug intelligence / Profile preview

kuihuapan

Development stage: Unknown
Lead developer: China SXT Pharmaceuticals
Administration: Oral

Overview

Kuihuapan is a Traditional Chinese Medicine Piece (TCMP) product developed and commercialized by China SXT Pharmaceuticals. It is produced according to the four processing specifications of the Chinese Pharmacopoeia (2020 Edition) No. 34, as approved by the Heilongjiang Food and Drug Administration. Kuihuapan is classified as an "After-Soaking-Oral TCMP" and is indicated for clearing heat, calming the liver, dredging collaterals, and relieving pain. Its primary indications include dizziness, tinnitus, joint pain, hyperuricemia, gout, hypertension, and related symptoms[4]. The product reflects traditional herbal medicine practices rather than a single defined chemical entity.

Brand names: Kuihuapan
Other names: Kuihuapan

Beyond the preview

Go deeper on kuihuapan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kuihuapan.

Explore the full profile